Advances in the Management of Pulmonary Arterial Hypertension (PAH)
Pulmonary arterial hypertension (PAH) is estimated to afflict approximately 100 000 to 200 000 people worldwide, many of whom are children and young women. PAH is caused by progressive narrowing of the distal precapillary pulmonary vasculature, leading to increased vascular resistance, shortness of breath, limitation of activity, right ventricular failure and death. Bosentan (Tracleer ® 1 ), a nonselective endothelin receptor antagonist, is the first orally administered drug approved by the US Food and Drug Administration (FDA) for the treatment of patients with PAH. It acts by blocking the binding of endothelin, a potent endogenous peptide with vasoconstrictor, mitogenic and profibrotic effects.
Profiling the Safety of Bosentan
At the American Thoracic Society (ATS) 2005 meeting, Actelion announced results from the European Surveillance Programme detailing the long-term (3-year) safety profile of bosentan in 5000 patients with PAH amounting to 3416 patientyears of treatment. [1] Bosentan was approved in Europe in May 2002 under exceptional circumstances as a result of positive phase III data. A provision of the approval was ongoing safety monitoring for a period of 3 years. The TRAX PMS (TRAcleer eXcellence Post-Marketing Surveillance) programme was put in place to meet this provision.
The TRAX PMS data confirmed the safety profile of bosentan as seen in phase III clinical trials and represented the completion of the largest noninterventional study to date of patients treated with bosentan for PAH in daily medical practice. [1] In particular, liver enzyme measurements showed that elevated ALT and/or AST values were reported in 7.7% of patients compared with 11% in the phase III clinical trials. Approximately 50% of those patients with elevated AST/ALT were maintained on bosentan with careful follow-up in line with approved labelling.
Combining Bosentan and Sildenafil
Sildenafil is currently being used off-label alone or in addition to bosentan in patients with PAH. The safety of combining sildenafil with bosentan is unknown. The safety profile in patients receiving the combination of bosentan and sildenafil was evaluated by a subanalysis of the TRAX data in 218 patients receiving both agents. [2] Median exposure to bosentan + sildenafil was 12.4 weeks. Elevated liver transaminase levels were noted in 6% in patients on bosentan + sildenafil versus 7.6% in those patients not treated with sildenafil. Safety findings in the bosentan + sildenafil group were generally comparable with those in patients receiving bosentan alone. According to these data taken from clinical practice, the combination of bosentan + sildenafil appears to be well tolerated.
Dr Marius Hoeper from the University of Hanover Medical School in Germany commented that "it is important to further confirm if sildenafil can be safely used in patients receiving treatment with bosentan as it would appear to be a useful additional therapy for some patients being treated for PAH."
Making STRIDEs in PAH Therapy
Sitaxsentan (Thelin™) is an oral, once-daily, highly selective endothelin receptor A antagonist pharmacologically distinct from bosentan. Although the relative importance of endothelin A and endothelin B receptors in PAH remains unclear, selective antagonism of endothelin A may be advantageous in blocking the deleterious endothelin A receptor-associated vasoconstriction in the pulmonary vasculature while maintaining the vasodilator and clearance functions associated with the endothelin B receptor.
Encysive Pharmaceuticals presented data from STRIDE-2 (Sitaxsentan to Relieve Impaired Exercise), the company's second pivotal phase III clinical trial of sitaxsentan for the treatment of PAH. [3] The data were presented by Robyn Barst, Professor of Pediatrics at the Columbia University College of Physicians and Surgeons and Director of the New York Presbyterian Hospital Pulmonary Hypertension Center, New York.
The goal of STRIDE-2 was to evaluate the efficacy and safety of sitaxsentan compared with placebo in the treatment of patients with PAH. A cohort of patients was randomised to an open-label bosentan arm for observational comparisons of efficacy and safety. A total of 246 patients with primary or secondary PAH were enrolled at 55 centres in North America, Europe, Israel and Australia in a double-blind 18 weeks study. Sitaxsentan met the primary endpoint of improved 6-minute walk distance (6MW); patients treated with sitaxsentan 100 mg/day showing a significant increase of 31.4 metres over placebo. Bosentan increased the 6MW over placebo by 29.5 metres. At the 18-week mark, patients treated with sitaxsentan continued to show improvement from week 12 while those treated with bosentan showed a downward trend beyond week 12. In addition, sitaxsentan therapy improved World Health Organization (WHO) Functional Class versus placebo while bosentan failed to do so. There was a trend for sitaxsentan showing a benefit over both bosentan and placebo on time to first clinical worsening. A 50mg dose of sitaxsentan did not achieve statistical significance over placebo in the primary endpoint.
The incidence of adverse effects was more frequent in sitaxsentan-treated patients than in placebo recipients. Commonly reported adverse events included headache, oedema, nausea, upper respiratory tract infections, dizziness, insomnia, nasopharyngitis and nasal congestion. Sitaxsentan 100 mg/day was associated with a 3% incidence of liver function abnormality compared with 11% for bosentan and 6% for placebo.
STRIDE-6 was a multicentre 12-week study of sitaxsentan 50 or 100 mg/day given to 48 patients, 35 of whom had discontinued bosentan for inadequate clinical response and the remaining 13 for safety reasons. [4] Using a 15% improvement threshold for 6MW, 33% of patients who had discontinued bosentan because of a lack of efficacy showed improvement in 6MW when treated with sitaxsentan 100mg. Disease progression of >15% was seen in 15-20% of patients. Similarly, 27% of patients treated with sitaxsentan 100 mg/day showed an improvement in Borg dyspnoea score and 7% in WHO Functional Class. None of the patients in this subset developed abnormal liver function. Of 13 patients who discontinued bosentan due to hepatotoxicity, none experienced deterioration in 6MW or had a >1 point increase in Borg dyspnoea score and only 1 patient showed elevated hepatic transaminases in either sitaxsentan group. No patient in this safety-failure subset experienced a clinical worsening event.
Study investigators concluded that sitaxsentan 100 mg/day is a viable treatment option for PAH patients who discontinue bosentan due to safety issues or inadequate clinical response. However, close monitoring is required to identify patients with PAH who continue to deteriorate on sitaxsentan in order to institute appropriate prostacyclin-based therapy.
Emerging Concepts in Asthma
As the understanding of the pathophysiology of asthma continues to improve, new therapies are being developed to block the immune response before it triggers inflammation. One such treatment, the anti-IgE agent omalizumab, had been shown to reduce markers of inflammation in patients with asthma as well as reduce exacerbations while allowing a decrease in the dose of inhaled corticosteroids.
Two poster presentations from Novartis highlighted the impact of add-on omalizumab (Xolair ® ) on the rate of severe asthma exacerbations and quality of life in patients with severe persistent asthma despite GINA (Global Initiative for Asthma) step 4 therapy (high-dose inhaled corticosteroids + long-acting β-agonists + oral corticosteroids).
Add-On Omalizumab Has Positive Effect
Patients were randomised to omalizumab or placebo for 28 weeks in a double-blind, parallel-group, multicentre study (INNOVATE). [5] 419 patients were included in the efficacy analyses. All patients received inhaled corticosteroids plus long-acting β-agonists and two-thirds received additional controller medication. Add-on omalizumab therapy halved the severe exacerbation rate and reduced emergency room visits by 44%. The investigators concluded that omalizumab should be considered as add-on therapy for patients with inadequately controlled severe persistent asthma who have a significant unmet need despite best available therapy.
The INNOVATE study included quality-of-life (QOL) analyses. [6] Add-on omalizumab therapy produced significantly greater improvements than placebo for each individual Asthma QOL Questionnaire domain and overall score. A significantly greater proportion of patients receiving omalizumab achieved a clinically meaningful ≥0.5-point improvement from baseline in Asthma QOL Questionnaire score than placebo recipients (61% vs 48%).
Moving Towards a New Age in Asthma Management
Coadministration of an inhaled corticosteroid (ICS) with a long-acting β 2 -adrenoceptor agonist (β 2 -agonist) in a single inhaler has greatly simplified asthma therapy. The two combination inhalers currently available, budesonide/formoterol (Symbicort ® ) and salmeterol/fluticasone propionate (Seretide™) comply with step 3 of international guidelines that recommend the addition of a long-acting β 2 -agonist to ICS in patients who are inadequately controlled on ICS alone. Combination inhalers ensure that patients cannot neglect their ICS maintenance therapy in favour of the long-acting β 2 -agonists thus improving adherence and overall asthma control.
There are currently 2 approaches to treating asthma using combination therapy; i.e. fixed and adjustable dosing. Fixed treatment with budesonide/formoterol or salmeterol/fluticasone propionate provides effective asthma control in line with guideline goals. However, given the inherent variability of asthma, there is increasing evidence that adjusting the dose of ICS according to fluctuations in symptoms is beneficial. Adjustable dosages improves asthma control at an overall lower corticosteroid dose.
At the ATS meeting, AstraZeneca reported that its novel treatment regimen, budsonide/formoterol maintenance and reliever therapy (Symbicort ® Single Inhaler Therapy™ [SiT]) delivered greater improvement in key measures of asthma control and simplified management compared with GlaxoSmithKline's salmeterol/fluticasone propionate. COSMOS was the first 'reallife', 1-year, head-to-head trial of two commonly used combination therapies for asthma -a traditional fixed-dose treatment approach as used with salmeterol/fluticasone propionate which requires the use of separate maintenance and reliever inhalers in contrast to adjustable dosages with budesonide/formoterol in a single inhaler containing both maintenance and reliever medication. Results of the COSMOS trial were presented at 2 poster sessions. [7, 8] The open-label study involved 2143 adult and adolescent patients with moderate-to-severe asthma treated with budesonide/ formoterol for both maintenance and as-needed relief (Symbicort ® SiT) or salmeterol/fluticasone propionate (Seretide™). Budesonide/formoterol for both maintenance and relief prolonged the time to first severe exacerbation over 12 months, compared with salmeterol/fluticasone propionate titrated according to physician judgement. In addition, patients treated with budesonide/formoterol for both maintenance and relief experienced fewer asthma attacks and used less rescue medication compared with all doses of salmeterol/fluticasone propionate.
While presenting the data Professor Claus Vogelheimer from Marburg University, Germany, commented the "[r]esults from the COSMOS trial show for the first time that Symbicort ® , when used as maintenance and reliever therapy, reduces the risk of developing a severe asthma exacerbation in comparison to Seretide™ as maintenance plus salbutamol as reliever. Symbicort ® Single Inhaler Therapy™ is a unique management approach using a simplified treatment regimen. Not only is one inhaler more convenient for patients to use but Symbicort ® can also achieve excellent asthma control, potentially impacting on future treatment guidelines."
The full effect on the exacerbation burden was exemplified by a 34% reduction in oral corticosteroid days and a 37% reduction in hospital days with Symbicort ® SiT. It is possible to use budesonide/formoterol for both maintenance and symptom relief because formoterol has a more rapid onset and greater doserelated effects compared with the salmeterol component in Seretide™.
Patient-Centred Outcomes in Chronic Obstructive Pulmonary Disease
To date no intervention besides smoking cessation has been conclusively shown to alter the rate of decline in lung function in patients with chronic obstructive pulmonary disease (COPD). Tiotropium bromide (Spiriva ® ), which acts primarily through the blockade of muscarinic receptors, is the first inhaled medication available to COPD patients providing 24-hour bronchodilation with once-daily administration, and providing significant and sustained improvement in lung function.
Patients with COPD experienced statistically and clinically significant improvements in health-related QOL following 9 months' treatment with tiotropium bromide according to results of the TIPHON 2 study presented in a poster presentation. [9] Five hundred and fifty-four patients with moderate COPD were randomised to tiotropium bromide or placebo. Healthrelated QOL was evaluated using the Saint George's Respiratory Questionnaire (SGRQ) and the Visual Simplified Respiratory Questionnaire (VSRQ) developed specifically for the study. Results from TIPHON (the first study with tiotropium bromide to assess change in health status as the primary endpoint) showed that:
• significantly more patients treated with tiotropium bromide experienced a four-point improvement in SGRQ than those receiving placebo (59% vs 48%) • tiotropium-treated patients had a statistically significant improvement in their VSRQ score compared with placebo recipients.
The benefits of tiotropium bromide were found to be independent of the use of ICS or reversibility status at study entry. Additional study findings in patients treated with tiotropium bromide included significant and sustained improvements in lung function compared with the placebo group.
"The TIPHON study results are encouraging because they show that treatment with Spiriva ® can result in clinically significant and sustained improvements in health-related quality of life for patients with COPD", said the study's lead investigator Dr Andre-Bernard Tonnel, Service de Pneumologie et ImmunoAllergologie, Centre Hospitalier Regional et Universitaire de Lille, France. "Improved health status, or quality of life, is one of the main parameters for judging efficacy of prescribed therapies in daily practice."
Promising Phase II Data for Indacaterol
Long-acting β 2 -agonists such as formoterol and salmeterol, alone or in combination with corticosteroids, constitute an established treatment for asthma and COPD. Although formoterol and salmeterol have a much longer duration of action than the shortacting β 2 -agonists, they still need to be inhaled twice daily for optimal effect. Novartis' pipeline compound indacaterol (QAB 149) may provide a new standard for β 2 -agonist therapy in patients with asthma and COPD according to data presented at the ATS meeting. The collective data from the phase II studies showed that indacaterol provided:
• 24-hour control of bronchodilation with once-daily administration; [10] • favourable cardiovascular safety profile with no clinically significant effect on ECG measurements, vital signs or laboratory tests commonly affected by long-acting β-agonists; [11] • fast onset of action comparable to the short-acting β-agonist salbutamol. [12] 6. The Scleroderma Lung Study: Lessons for Interstitial Lung Disease A drug that suppresses the immune system and reduces inflammation was shown to be effective in treating lung disease associated with the devastating connective tissue disease scleroderma. The Scleroderma Lung Study sponsored by the US National Institutes of Health (NIH) is the first large trial to study the effectiveness of cyclophosphamide against scleroderma lung disease. Scleroderma is a systemic immune disorder characterised by inflammation and fibrosis involving the skin and internal organs including the lungs. Pulmonary complications are the most common cause of death.
The randomised, double-blind placebo-controlled study involved 162 patients who had pulmonary scleroderma for an average of 3 years at study entry and showed active inflammation in the lung. Oral cyclophosphamide 1-2 mg/kg/day for 1 year produced significant but modest improvement in lung function (FVC % predicted), significantly less worsening of breathlessness (Transitional Dyspnea Index >1 unit) and better functional ability (Health Assessment Questionnaire -Disability Index).
"Until now, there has been no proven therapy for scleroderma, and 60-70% of patients die within 10 years", said Donald Tashkin, Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles, one of the study's authors.
The researchers reported more serious adverse events in the cyclophosphamide group compared with the placebo group including pneumonia (5 cases vs 1 in the placebo group) and leukopenia (19 vs 0 in the placebo group). "Nobody died of toxicity from the drug", said Dr Tashkin. "We know cyclophosphamide has toxic effects, but you have to balance the efficacy of the drug against its toxicity. It's a desperate disease, and nothing else has proven effective. We feel the benefits outweigh the risks."
The extent of fibrosis on the baseline thoracic high-resolution CT had a significant influence on the treatment effect. Additional exploratory analyses are in progress to evaluate further possible predictors of response to cyclophosphamide treatment. The observed benefits of treatment with cyclophosphamide need to be weighed against its toxicity (benefit/risk ratio). Outcomes of drug combinations with cyclophosphamide will be investigated in the future.
